Insomnia – Current Treatment – Current Treatment: Physician Insights – Insomnia (EU5)
Insomnia is a common sleep disorder characterized by difficulty initiating or maintaining sleep, leading to impaired daytime functioning. Its management is highly personalized, with clinicians considering multiple patientspecific factors when selecting therapy. In the EU5, insomnia is increasingly recognized as a distinct clinical condition, and clinical practice aligns with updated European Sleep Research Society (ESRS) guidelines, which emphasize structured clinical interviews, sleep diaries, and validated diagnostic tools. Although generic Zdrugs (e.g., zolpidem), antidepressants (e.g., amitriptyline), and benzodiazepines (e.g., diazepam) have historically dominated treatment, the growing adoption of DORAs—particularly Idorsia Pharmaceuticals’ Quviviq—is reshaping the treatment paradigm in the region. This report examines the factors influencing prescriber decisionmaking, evaluates clinician perceptions of current therapies, analyses prescribing patterns, and highlights key remaining areas of unmet need in the management of insomnia.
Questions answered
- What factors drive or constrain GPs / psychiatrists / sleep specialists’ treatment decisions for insomnia?
- How do product shares vary across lines of therapy? To what extent are high-efficacy therapies (e.g., Quviviq) influencing early-line treatment choices?
- How has the availability of DORAs affected the prescribing patterns of non-benzodiazepine hypnotic therapies?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
Geography: France, Germany, Italy, Spain, United Kingdom
Primary research: Survey of 75 EU5 psychiatrists, 75 EU5 sleep specialists, and 100 EU5 GPs
Key drugs: Quviviq, Trazodone, Zolpidem, Zopiclone
Key analyses
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician insight on persistency and compliance
